Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Pfizer (NYSE:PFE) received its first Chinese approval for obesity drug Severwin, opening access to a major new treatment ...